{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:47:30Z","timestamp":1792799250675,"version":"4.5.0"},"reference-count":23,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aimed to investigate the safety, tolerability, and efficacy of daily TransCon PTH in adults with hypoparathyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 2, randomized, double-blind, placebo-controlled 4-week trial with open-label extension enrolled 59 individuals with hypoparathyroidism. Interventions included TransCon PTH 15, 18, or 21 \u00b5g PTH(1-34)\/day or placebo for 4 weeks, followed by a 22-week extension during which TransCon PTH dose was titrated (6-60 \u00b5g PTH[1-34]\/day).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By Week 26, 91% of participants treated with TransCon PTH achieved independence from standard of care (SoC, defined as active vitamin D\u2005=\u20050 \u03bcg\/day and calcium [Ca]\u2005\u2264\u2005500 mg\/day). Mean 24-hour urine Ca (uCa) decreased from a baseline mean of 415 mg\/24h to 178 mg\/24h by Week 26 (n\u2005=\u200544) while normal serum Ca (sCa) was maintained and serum phosphate and serum calcium-phosphate product fell within the normal range. By Week 26, mean scores on the generic 36-Item Short Form Health Survey domains increased from below normal at baseline to within the normal range. The Hypoparathyroidism Patient Experience Scale symptom and impact scores improved through 26 weeks. TransCon PTH was well tolerated with no treatment-related serious or severe adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TransCon PTH enabled independence from oral active vitamin D and reduced Ca supplements (\u2264\u2005500 mg\/day) for most participants, achieving normal sCa, serum phosphate, uCa, serum calcium-phosphate product, and demonstrating improved health-related quality of life. These results support TransCon PTH as a potential hormone replacement therapy for adults with hypoparathyroidism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgab577","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T12:26:03Z","timestamp":1628079963000},"page":"e372-e385","source":"Crossref","is-referenced-by-count":77,"title":["PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism"],"prefix":"10.1210","volume":"107","author":[{"given":"Aliya A","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism and Geriatrics, McMaster University, Hamilton, Ontario L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rejnmark","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela","family":"Rubin","sequence":"additional","affiliation":[{"name":"Metabolic Bone Disease Unit, Columbia University, New York, New York 10027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Rigshospitalet, Copenhagen and Faculty of Health Sciences, Copenhagen University, 2200 Copenhagen N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Vokes","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, Illinois 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intekhab","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Hofbauer","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-8588","authenticated-orcid":false,"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[{"name":"University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Diabetes, Campus Bio-Medico University, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, Institute of Clinical Medicine, 0372 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl","family":"Brod","sequence":"additional","affiliation":[{"name":"The Brod Group, Mill Valley, California 94941, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denka","family":"Markova","sequence":"additional","affiliation":[{"name":"Ascendis Pharma Inc , Palo Alto, California 94301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden","family":"Smith","sequence":"additional","affiliation":[{"name":"Ascendis Pharma Inc , Palo Alto, California 94301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Pihl","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchita","family":"Mourya","sequence":"additional","affiliation":[{"name":"Ascendis Pharma Inc , Palo Alto, California 94301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Karpf","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5289","authenticated-orcid":false,"given":"Aimee D","family":"Shu","sequence":"additional","affiliation":[{"name":"Ascendis Pharma Inc , Palo Alto, California 94301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"issue":"7","key":"2021121823120492600_CIT0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM197308162890710","article-title":"The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3, a calcium-mobilizing hormone","volume":"289","author":"DeLuca","year":"1973","journal-title":"N Engl J Med."},{"issue":"18","key":"2021121823120492600_CIT0002","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM197711032971804","article-title":"Basic and clinical concepts related to vitamin D metabolism and action (first of two parts)","volume":"297","author":"Haussler","year":"1977","journal-title":"N Engl J Med."},{"issue":"19","key":"2021121823120492600_CIT0003","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197711102971906","article-title":"Basic and clinical concepts related to vitamin D metabolism and action (second of two parts)","volume":"297","author":"Haussler","year":"1977","journal-title":"N Engl J Med."},{"issue":"15","key":"2021121823120492600_CIT0004","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM198904133201506","article-title":"The role of the vitamin D endocrine system in health and disease","volume":"320","author":"Reichel","year":"1989","journal-title":"N Engl J Med."},{"issue":"12","key":"2021121823120492600_CIT0005","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021121823120492600_CIT0006","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121823120492600_CIT0007","author":"Center for Drug Evaluation and Research","year":"2014"},{"issue":"8","key":"2021121823120492600_CIT0008","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"11","key":"2021121823120492600_CIT0009","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2021121823120492600_CIT0010","volume-title":"Med Care","author":"Ware"},{"key":"2021121823120492600_CIT0011","volume-title":"User\u2019s manual for the SF-36v2 Health Survey.","author":"Maruish","edition":"3rd"},{"issue":"2","key":"2021121823120492600_CIT0012","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121823120492600_CIT0013","first-page":"5(1):70","article-title":"Psychometric validation of the hypoparathyroidism patient experience scales (HPES)","author":"Brod","year":"2021","journal-title":"J Patient Rep Outcomes."},{"issue":"11","key":"2021121823120492600_CIT0014","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021121823120492600_CIT0015","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021121823120492600_CIT0016","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/BF03346763","article-title":"Use of parathyroid hormone in hypoparathyroidism","volume":"36","author":"Cusano","year":"2013","journal-title":"J Endocrinol Invest."},{"issue":"2","key":"2021121823120492600_CIT0017","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121823120492600_CIT0018","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00198-018-04819-1","article-title":"Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE","volume":"30","author":"Eastell","year":"2019","journal-title":"Osteoporos Int."},{"issue":"11","key":"2021121823120492600_CIT0019","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2021121823120492600_CIT0020","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2021121823120492600_CIT0021","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4158\/EP13328.OR","article-title":"Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study","volume":"20","author":"Hadker","year":"2014","journal-title":"Endocr Pract."},{"issue":"1","key":"2021121823120492600_CIT0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12020-017-1377-3","article-title":"Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review","volume":"58","author":"B\u00fcttner","year":"2017","journal-title":"Endocrine."},{"issue":"4","key":"2021121823120492600_CIT0023","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ecl.2018.07.001","article-title":"Signs and symptoms of hypoparathyroidism","volume":"47","author":"Cusano","year":"2018","journal-title":"Endocrinol Metab Clin North Am."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab577\/40328827\/dgab577.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e372\/41819574\/dgab577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e372\/41819574\/dgab577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T18:14:32Z","timestamp":1639851272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/1\/e372\/6340040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,4]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab577","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,4]]}}}